Brought to you by 
Novartis partners Phase II CNS compound with Vanda
29 Dec 2014
Executive Summary
Concurrent with settling arbitration proceedings over their previously partnered schizophrenia drug Fanapt (iloperidone), Novartis AG licensed Vanda Pharmaceuticals Inc. exclusive global rights to its Phase II CNS compound AQW051. The transaction also includes patents, patent applications, and other IP.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis partners Phase II CNS compound with Vanda
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice